Guardant Health surges 15% on boosted revenue guidance range, Q3 beats
filo Guardant Health (NASDAQ:GH) is up ~15% in after-hours trading Wednesday after reporting Q3 results that beat on both lines and raising its 2024 revenue outlook. The precision oncology company now sees full-year revenue to be $720M-$725M, compared to $690M-$700M prior. Consensus is $695.47M. In the quarter, the company's non-GAAP net loss narrowed to ~$55M from ~$79.2M in the year-ago period (-$0.45 per share basic and diluted vs -$0.67). Guardant Health ended the quarter (Sept. 30) with cash, cash equivalents, and restricted cash of ~$688.4M compared to ~$1.1B on Dec. 31, 2023.
Disclaimer: The views in this article are from the original Creator and do not represent the views or position of Hawk Insight. The content of the article is for reference, communication and learning only, and does not constitute investment advice. If it involves copyright issues, please contact us for deletion.
